» Articles » PMID: 29977500

Levothyroxine Pseudo-malabsorption: Testing and Treatment in the Outpatient Setting

Overview
Specialty Endocrinology
Date 2018 Jul 7
PMID 29977500
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Persistent elevation of thyroid stimulating hormone (TSH) is a common clinical problem in outpatient clinics treating patients with primary hypothyroidism. One challenge to practitioners involves predicaments where patients have an inadequate response to a seemingly appropriate dose of levothyroxine (L-T4). A patient's self-assessed compliance to hormone replacement therapy or verification refill history at the patient's pharmacy might not be a reliable form of confirmation of non-adherence to the drug by the patient, which has been referred to as "L-T4 pseudo-malabsorption." A fast and inexpensive tool to rule out true LT4 malabsorption and thereby properly diagnosing and ultimately successfully treat LT4 pseudo-malabsorption is available in the outpatient setting. This allows clinicians to identify which patients for individual support in adhering to their prescribed therapy and may also reduce unnecessary referrals for sub-specialty care by endocrinologists.

Citing Articles

Levothyroxine: Conventional and Novel Drug Delivery Formulations.

Liu H, Li W, Zhang W, Sun S, Chen C Endocr Rev. 2022; 44(3):393-416.

PMID: 36412275 PMC: 10166268. DOI: 10.1210/endrev/bnac030.


Levothyroxine malabsorption or pseudomalabsorption? A question in the management of refractory hypothyroidism.

Santos Monteiro S, Santos T, Lopes A, Oliveira J, Freitas C, Couto Carvalho A Endocr Connect. 2022; 11(12).

PMID: 36318199 PMC: 9716372. DOI: 10.1530/EC-22-0355.


REFRACTORY HYPOTHYROIDISM TO LEVOTHYROXINE TREATMENT: FIVE CASES OF PSEUDOMALABSORPTION.

Elbasan O, Yavuz D Acta Endocrinol (Buchar). 2020; 16(3):339-345.

PMID: 33363657 PMC: 7748222. DOI: 10.4183/aeb.2020.339.


Managing symptoms in hypothyroid patients on adequate levothyroxine: a narrative review.

Razvi S, Mrabeti S, Luster M Endocr Connect. 2020; 9(11):R241-R250.

PMID: 33112818 PMC: 7774765. DOI: 10.1530/EC-20-0205.


Levothyroxine Absorption Test to Differentiate Pseudomalabsorption from True Malabsorption.

Ghosh S, Pramanik S, Biswas K, Bhattacharjee K, Sarkar R, Chowdhury S Eur Thyroid J. 2020; 9(1):19-24.

PMID: 32071898 PMC: 7024890. DOI: 10.1159/000504218.


References
1.
Ain K, Refetoff S, Fein H, Weintraub B . Pseudomalabsorption of levothyroxine. JAMA. 1991; 266(15):2118-20. View

2.
NORTHCUTT R, Stiel J, Hollifield J, STANT Jr E . The influence of cholestyramine on thyroxine absorption. JAMA. 1969; 208(10):1857-61. View

3.
Centanni M . Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine. 2012; 43(1):8-9. DOI: 10.1007/s12020-012-9814-9. View

4.
Hamed S . The effect of antiepileptic drugs on thyroid hormonal function: causes and implications. Expert Rev Clin Pharmacol. 2015; 8(6):741-50. DOI: 10.1586/17512433.2015.1091302. View

5.
Singh N, Weisler S, Hershman J . The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid. 2001; 11(10):967-71. DOI: 10.1089/105072501753211046. View